Annals Internal Medicine and U.S. Preventive Services Task Force fingono di ignorare il Reale Rischio Congenito di CAD!

Nel corrente numero della “celebre” rivista statunitense Annals of Internal Medicine, alla URL https://annals.org/article.aspx?articleid=1262305 si può leggere l’articolo “Screening for Coronary Heart Disease With Electrocardiography: U.S. Preventive Services Task Force Recommendation Statement”,  Virginia A. Moyer, MD, MPH; and on behalf of the U.S. Preventive Services Task Force  Ann Intern Med. 31 July 2012.

Gli Autori, gli Editori e Revisori di Ann Intern Med., i Membri dell’U.S. Preventive Services Task Force, evidentemente  non sono aggiornati,  pretendono di aggiornare i Medici: ignorano il Reale Rischio Congenito di CAD, inrete persino nel sito della rivista: RIDICOLI! Stagnaro Sergio. Biophysical-Semeiotic Inherited Coronary Real Risk, conditio sine qua non of CAD.17 August 2007. http://www.annals.org/cgi/eletters/0000605-200708070-00167v1#19068

Nessun cardiologo, inclusi i Membri della SID,  nessun “Professore” al mondo oserebbe  negare l’esistenza del RRC di CAD, alla luce delle pubblicazioni seguenti:

Stagnaro Sergio. Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning – c007i. Lecture, V Virtual International Congress of Cardiology, 2007. http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php ;

Stagnaro Sergio.    CAD Inherited Real Risk, Based on Newborn-Pathological, Type I, Subtype B, Aspecific, Coronary Endoarteriolar Blocking Devices. Diagnostic Role of Myocardial Oxygenation and Biophysical-Semeiotic Preconditioning.International Atherosclerosis Society. www.athero.org, 29 April, 2009  http://www.athero.org/commentaries/comm907.asp;

Stagnaro Sergio.  Bedside recognizing Inherited CAD Real Risk. www.natura.com 21 May, 2008. http://network.nature.com/forums/pmgs/1587?page=1#reply-4262;

Stagnaro Sergio. Bedside Recognizing CAD Inherited Real Risk and silent CAD with Biophysical Semeiotics. Lipid in Health and Disease. (29 May 2008) http://www.lipidworld.com/content/7/1/19/comments#299588;

Stagnaro Sergio.   Bedside Evaluation of CAD biophysical-semeiotic inherited real risk under NIR-LED treatment. EMLA Congress, Laser Helsinki August 23-24, 2008. “Photodiagnosis and photodynamic therapy”, Elsevier, Vol. 5 suppl 1 august 2008 issn 1572-1000;

Sergio Stagnaro (2012).  I Segni di Caotino* e di Gentile** nella Diagnosi di Reale Rischio Congenito di CAD e di Infarto Miocardico, ancorché iniziale o silente. Fisiopatologia e Terapia. Lectio Magistralis. III Convegno della SISBQ, 9-10 Giugno 2012, Porretta Terme (Bologna).  www.sisbq.org. http://www.sisbq.org/uploads/5/6/8/7/5687930/presentazione_stagnaro_it.pdf

Purtroppo, i “Professori”  non soltanto tacciono, non osano esprimere giudizi sul CAD IRR e quindi la sua  mancata diffusione tra i Medici spiega il perché la CAD è una epidemia in continuo aumento.

Infatti, ecco la desolante e puerile conclusione del citato articolo.

“The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening with resting or exercise ECG for the prediction of CHD events in asymptomatic adults at intermediate or high risk for CHD events (I statement)”.

E’ impensabile che  i suddetti ignorino la morte “improvvisa ed imprevista” di tanti Atleti Professionisti, controllati da cardiologi famosi,  perché  dispongono di Laboratori e di Dipartimenti delle Immagini sofisticatissim.

Che bisogno c’era di una ricerca da scolaretto di G. Bateson come quella pubblicata sui  “celebri”  Ann Intern Med? Tutti sanno che l’ECG di base o da sfornzo NON permette il rilievo del Reale Rischio Congneito di CAD.

Ho inviato DUE commenti agli Editori della rivista: prevedo che non saranno pubblicati a causa del mio inglese da autodidatta!!!

Ho scritto anche a U.S. Preventive Services Task Force. ECCO LA RISPOSTA AUTOMATICA:

Your question has been received. You should expect a response from us
within 24 hours.

Question Reference #120802-000000
—————————————————————
Summary: Do we want really win CAD, type2 Diabetes Mellitus
and Cancer, today’s growing epidemics?
Category Level 1: News and Information
Category Level 2: Freedom of Information Act (FOIA)
Date Created: 08/02/2012 03:51 AM
Last Updated: 08/02/2012 03:51 AM
Status: Unresolved
Name: Sergio Stagnaro
Telephone Number: 0039-0185-42

Mailing Address
—————————————————————
Via Erasmo Piaggio 23/8
16039, Riva Trigoso – Genoa – Italy
Discussion Thread
—————————————————————
Customer By Web Form  – 08/02/2012 03:51 AM
Firstly, visit kinly following websites: [link removed] and [link removed]
Secondly, let me know what accounts for the reason you are serching for screening CAD, type 2 DM, and Cancer, ovelooking Quantum Biophysical Semeiotics.
Finally, answer please to my question: “Do we want really win CAD, type2 Diabetes Mellitus and Cancer, today’s growing epidemics?”
Sergio Stagnaro MD
Via Erasmo Piaggio 23/8,
16039 Riva Trigoso (Genoa) Italy
Founder of Quantum Biophysical Semeiotics,
Honorary President of  International Society of
Quantum Biophysical Semeiotics  (SISBQ)
Who’s Who in the World (and America)
since 1996
Ph 0039-0185-42315
Cell. 3338631439

Vi informerò sui futuri eventi.

 

 

Pubblicità

NEJM, Letter to Editors ID 12-00779: Epilogo prevedibile!

Con una risposta “automatica”, dopo 31 giorni di valutazione “competente”, onesta e libera ecco come gli Editori del NEJM spiegano i motivi della mancata pubblicazione della Lettera il cui testo è leggibile avanti:

21 February 2012, 17,04

letter@nejm.org

Dear Dr. Stagnaro,
I am sorry that we will not be able to print your recent letter to the editor regarding the Jackevicius article of 19-Jan-2012.  The space available for correspondence is very limited, and we must use our judgment to present a representative selection of the material received.  Many worthwhile communications must be declined for lack of space.
Thank you for your interest in the Journal.

Sincerely,

Debra Malina, Ph.D.
Perspective Editor
New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org

My answer:

Debra Malina, Ph.D.
Perspective Editor
New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org,

CAD Inherited Real Risk, sufficiently spread among physicians around the world,  even in your website, is the clinical tool most efficient in the war against CAD growing epidemics.
Thus, we shall  win surely, though later, because of your “automatic”, forseen, decision….

Sergio Stagnaro

Sergio Stagnaro MD
Via Erasmo Piaggio 23/8
16039 Riva Trigoso (Genoa) Italy
Founder of Quantum Biophysical Semeiotics
Who’s Who in the World (and America)
since 1996
Honorary President of International Society of
Quantum Biophysical Semeiotics
Ph 0039-0185-42315
Cell. 3338631439
www.semeioticabiofisica.it
www.sisbq.org
dottsergio@semeioticabiofisica.it

Ecco il testo della Lettera respinta dal NEJM:

Letter to NEJM Editors

Editors,

in Cynthia A. Jackevicius’s et al. paper (1), there is a fundamental bias: Not all dislipidemic are created equal!

In fact, not all hypertensives and/or diabetics and/or dyslipidemics and/or hyper-omocysteinemics, a.s.o.,  are suffering from CVD (2-5).

On the other hand, an awful number of individuals – as I am – are involved by AMI outcomes and million of other subjects  died of “sudden” AMI, though they were (and some are) negative for environmental risk factors, about 300, of CVD.

At this point, regarding the  “sudden” AMI, I state that the variant “sudden” of AMI does not exists, due to CAD Inherited Real Risk (2-5).

From the above remarks, it appears extremely necessary that in preventing CVD, today’s growing epidemics, before prescribing expensive statins, physicians enrol  only individuals at CVD inherited real risk, as you may read in a large Literature (2-5).  Doing so, in spite of the social, financial condition, every individual at inherited real risk of CVD will treated at the best.

References

1)      Jackevicius C.A., Pharm.D., Mindy M. Chou, Pharm.D., Joseph S. Ross, M.D., M.H.S., Nilay D. Shah, Ph.D., and Harlan M. Krumholz, M.D. Generic Atorvastatin and Health Care Costs. N Engl J Med 2012; 366:201-204January 19, 2012

 

2)      Stagnaro Sergio. Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning – c007i. Lecture, V Virtual International Congress of Cardiology. http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php

 

3)      Stagnaro Sergio.     Pre-Metabolic Syndrome and Metabolic Syndrome: Biophysical-Semeiotic Viewpoint. IAS. http://www.athero.org, 29 April, 2009. http://www.athero.org/commentaries/comm904.asp

 

4)      Stagnaro Sergio.    CAD Inherited Real Risk, Based on Newborn-Pathological, Type I, Subtype B, Aspecific, Coronary Endoarteriolar Blocking Devices. Diagnostic Role of Myocardial Oxygenation and Biophysical-Semeiotic Preconditioning. IAS. http://www.athero.org, 29 April, 2009.  http://www.athero.org/commentaries/comm907.asp

 

5)      Stagnaro Sergio. Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes.Eur J Clin Nutr. 2007 Feb 7; [MEDLINE]